e-Lung Computed Tomography Biomarker Stratifies Patients at Risk of Idiopathic Pulmonary Fibrosis Progression in a 52-Week Clinical Trial

e-Lung WRVS CT biomarker accurately predicted which patients were at risk of 52-week FVC decline. These data suggest that the e-Lung WRVS tool may allow enrichment of clinical trials for progressive patients, identify patients at low risk of IPF progression, and facilitate well-matched treatment arms. Further work is ongoing to validate these findings in additional cohorts.